Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Total Current Liabilities
All obligations due within one year.
Evommune, Inc.NYSE: EVMN
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 51.9% from a year ago
Total current liabilities stood at $10.6M at the end of Q1 FY2026, down 51.9% from a year earlier and down 40.8% from the prior quarter.
Context
- Total current liabilities amounted to 3.3% of total assets at the end of Q1 FY2026, down 36.1 pp from a year earlier.
- Total current liabilities increased in 1 of the last 2 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -51.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 17.91M USD
- Year-over-year change
- -36.0%
- 2-year CAGR
- +61.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.91M | -36.0% |
| FY2024 | 2024-12-31 | 27.98M | +308.1% |
| FY2023 | 2023-12-31 | 6.86M | — |
Total Current Liabilities vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 total current liabilities of $10.6M is the 9th highest of the 10 companies compared; the peer median is $37.46M.
- Its year-over-year change of -51.9% is the lowest of 10, against a peer median of -10.1%.
- Total current liabilities amounts to 3.3% of total assets for EVMN, versus a peer median of 11.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $963.7M | +2.3% | +9.3% | 35.5% |
| Sep 2026 | $161.46M | +284.0% | -23.8% | 13.7% | |
| Mar 2026 | $117.3M | +29.8% | +11.8% | 89.3% | |
| Jun 2026 | $46.74M | -27.8% | -27.6% | 2.1% | |
| Mar 2026 | $37.46M | -10.1% | +2.3% | 13.0% | |
| Mar 2026 | $14.85M | -29.0% | -19.8% | 11.5% | |
| Mar 2026 | $13.57M | +18.9% | -14.5% | 4.6% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $10.88M | -10.8% | -20.1% | 10.3% |
EVMNEvommune, Inc. | Mar 2026 | $10.6M | -51.9% | — | 3.3% |
CLYMClimb Bio, Inc. | Mar 2026 | $4.07M | -42.1% | +4.6% | 2.7% |
| Peer median (excluding EVMN) | $37.46M | -10.1% | -14.5% | 11.5% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.